|
Sephin1 reduces abnormal splicing during the recovery period after 1 h of arsenite stress. (A) Schematic of the experiment on SH-SY5Y. (B) Expression level of TDP-43 in nuclear fraction, RIPA-soluble fraction and RIPA-insoluble (urea) fraction during the recovery period after 1 h of arsenite treatment (n = 3 independent experiments). (C) Expression level of TDP-43 in nuclear fraction, RIPA-soluble fraction and RIPA-insoluble fraction during the recovery period after 1 h of arsenite treatment in SH-SY5Y treated with Sephin1 10 μM compared with SH-SY5Y treated with DMSO (n = 3 independent experiments). (D) Tardbp mRNA expression level in arsenite treated SH-SH5Y at 0, 3, and 6 h of recovery (n = 5 independent experiments). (E) Stmn2 WT mRNA expression level in arsenite treated SH-SY5Y at 0, 3, and 6 h of recovery (n = 5 independent experiments). (F) Poldip3-SE mRNA expression level in arsenite treated SH-SH5Y at 0, 3, and 6 h of recovery (n = 5 independent experiments). (G) Tardbp mRNA expression level at 0, 3, and 6 h of recovery in arsenite stressed SH-SY5Y treated with Sephin1 10 μM compared with SH-SY5Y treated with DMSO (n = 5 independent experiments). (H) Stmn2 WT mRNA expression level at 0, 3, and 6 h of recovery in arsenite stressed SH-SY5Y treated with Sephin1 10 μM compared with SH-SY5Y treated with DMSO (n = 5 independent experiments). (I) Poldip3-SE mRNA expression level at 0, 3 and 6 h of recovery in arsenite stressed SH-SY5Y treated with Sephin1 10 μM compared with SH-SY5Y treated with DMSO (n = 5 independent experiments). *P < 0.05, **P < 0.01 Friedman test followed by Dunn’s multiple comparison test; &P < 0.05 two-way ANOVA followed by Sidak’s multiple comparison test. Mean ± SEM.
|
